9 completed, 1 terminated, 1 unknown. 11 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 9, Terminated 1, Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Postmenopausal: new trials by email Literature Review of Postmenopausal trials Research Report on Postmenopausal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients Ribociclib, Trastuzumab, Letrozole - HER2-positive Breast Cancer, Postmenopausal | Phase 1 / Phase 2 | Unknown | Yonsei University | 95 | 2019-06-10 | 2022-05-10 |
| Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer Alisertib, Fulvestrant, Laboratory Biomarker Analysis - Estrogen Receptor Status, HER2/Neu Negative | Phase 2 | Completed | Mayo Clinic | 96 | 2017-07-06 | 2026-09-24 |
| Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer Bupropion 150 mg XL, Placebo - Breast Carcinoma, Cervical Carcinoma | Phase 2 | Completed | NRG Oncology | 230 | 2017-05-31 | 2026-07-10 |
| The PROMISE Study: Duavee in Women With DCIS Conjugated Estrogens/Bazedoxifene, Laboratory Biomarker Analysis, Pharmacological Study - Ductal Breast Carcinoma In Situ, Postmenopausal | Phase 2 | Completed | Northwestern University | 142 | 2017-01-01 | 2025-01-28 |
| Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer Laboratory Biomarker Analysis, Letrozole, Ribociclib - Estrogen Receptor Positive, Postmenopausal | Phase 2 | Completed | Mayo Clinic | 40 | 2016-07-08 | 2021-10-26 |
| A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors Tamoxifen, Ralimetinib (LY2228820 dimesylate) - Postmenopausal, Metastatic Breast Cancer | Phase 2 | Terminated | Centre Francois Baclesse | 8 | 2015-01-01 | 2017-05-24 |
| A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy Exemestane, Abiraterone acetate + Prednisone/ Prednisolone + Exemestane, Abiraterone acetate + Prednisone or Prednisolone - Metastatic ER+ Her2- Breast Cancer, Postmenopausal | Phase 2 | Completed | Janssen Research & Development, LLC | 297 | 2011-08-24 | 2019-04-11 |
| Study of Statin as Neo-Adjuvant Therapy in Postmenopausal Breast Cancer Atorvastatin - Breast Cancer, Postmenopausal | Phase 2 | Completed | Lund University Hospital | 50 | 2009-01-01 | 2012-04-13 |
| Dose Finding Study of Danggui Buxue Tang (Herbal Formula)on the Treatment of Menopausal Symptoms DBT-Danggui Buxue Tang - Postmenopausal | Phase 2 | Completed | Chinese University of Hong Kong | 60 | 2006-06-01 | 2008-12-18 |
| Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD risedronate, experimental - Postmenopausal | Phase 2 | Completed | Warner Chilcott | 370 | 2004-04-01 | 2013-04-17 |
| Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer Imatinib Mesylate, Letrozole - Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive | Phase 2 | Completed | M.D. Anderson Cancer Center | 59 | 2003-10-03 | 2020-01-27 |
Breast Neoplasms (6) · Ovarian Neoplasms (2) · Carcinoma, Intraductal, Noninfiltrating (1) · Fallopian Tube Neoplasms (1) · Neoplasm Metastasis (1) · Uterine Cervical Neoplasms (1) · Vaginal Neoplasms (1) · Vulvar Neoplasms (1)
Neoplasms (8) · Neoplasms by Site (7) · Breast Diseases (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Adnexal Diseases (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Gonadal Disorders (2) · Ovarian Diseases (2)
Letrozole (3) · ribociclib (2) · Abiraterone Acetate (1) · Atorvastatin (1) · Bupropion (1) · Estrogens, Conjugated (USP) (1) · Fulvestrant (1) · Imatinib Mesylate (1) · MLN 8237 (1) · Prednisolone (1) · Prednisone (1) · Risedronic Acid (1) · Tamoxifen (1) · Trastuzumab (1) · bazedoxifene (1)
Mayo Clinic (2) · Centre Francois Baclesse (1) · Chinese University of Hong Kong (1) · Janssen Research & Development, LLC (1) · Lund University Hospital (1) · M.D. Anderson Cancer Center (1) · NRG Oncology (1) · Northwestern University (1) · Warner Chilcott (1) · Yonsei University (1)
United States (7) · France (2) · Netherlands (2) · Poland (2) · South Korea (2) · Belgium (1) · Canada (1) · China (1) · Croatia (1) · Ireland (1) · Luxembourg (1) · Russia (1) · Spain (1) · Sweden (1) · Ukraine (1)
Banu Arun (1) · Carsten Rose, MD (1) · Christopher J Haines, FPOGS (1) · Debra Barton (1) · Gerardo Colon-Otero (1) · John Beary, MD (1) · Swati Kulkarni, MD (1) · Tufia C. Haddad, M.D. (1)
PMID 25925673, PMID 26504153, PMID 33109627, PMID 33292612, PMID 34882500, PMID 36892847
P30CA015083 (1), P30CA016672 (1), P30CA060553 (1), R01CA214893 (1), UG1CA189867 (1)